Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management
Authors:
- Enrico MaggiEMEnrico Maggi
- Andrea MatucciAMAndrea Matucci
- 1 June 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 11 (3) , 262-268
Abstract
The rapid expansion of the use of biologics has resulted in an increase in adverse drug reactions, some of which can be life-threatening, due to the immunogenicity of these new drugs. This review summarizes the current knowledge of the pathogenic mechanisms of biologics-induced hypersensitivity reactions and highlights the most useful diagnostic and prophylactic tools now available in the clinical management of immunogenicity associated with biologics. Over the last few years, many drug-related or patient-related factors contributing to the immunogenicity of biologics have been identified, thus allowing a better identification of patients at risk of reaction. Recent studies show that different mechanisms sustain hypersensitivity reactions toward biologics, and the application of novel methods for detecting antidrug antibodies has allowed the involvement of specific IgE isotypes. Additionally, experience with procedures of desensitization to biologics continues to grow. Considering the increased use of the biological therapies in different clinical conditions, the definition of diagnostic and prophylactic strategies represents an unavoidable necessity in the management of potentially reactive patients in order to improve the safety profile of biologics.Keywords
This publication has 57 references indexed in Scilit:
- A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patientsJournal of Immunological Methods, 2010
- Review and expert opinion on prevention and treatment of infliximab-related infusion reactionsBritish Journal of Dermatology, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Anaphylaxis: Lessons from mouse modelsJournal of Allergy and Clinical Immunology, 2007
- Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community settingBlood, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel diseaseActa Paediatrica, 2006
- Effects of protein aggregates: An immunologic perspectiveThe AAPS Journal, 2006
- Accoutumance médicamenteuse à l’infliximab dans la maladie de CrohnRevue des Maladies Respiratoires, 2005
- EVALUATION OF RECOMBINANT HUMAN SOLUBLE DIMERIC TUMOR NECROSIS FACTOR RECEPTOR FOR PREVENTION OF OKT3-ASSOCIATED ACUTE CLINICAL SYNDROME1,2Transplantation, 1996